CYP3A
8 drugs Infectious Disease
1
approved indications
8
Approved Drugs
6
Companies
4
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (6 companies)
✓ All 8 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (4 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Johnson & Johnson 2 drugs
Gilead Sciences 2 drugs
MACLEODS PHARMS LTD 1 drug
By Therapeutic Area
Other 5 drugs
Infectious Disease 3 drugs
Drugs by Company PRO
MACLEODS PHARMS LTD 1 drug
AbbVie 1 drug
Bristol-Myers Squibb 1 drug
Pfizer 1 drug
By Therapeutic Area
Other 5 drugs
LOPINAVIR AND RITONAVIR, KALETRA, GENVOYA, TYBOST +1 more
Infectious Disease 3 drugs
PREZCOBIX, SYMTUZA, PAXLOVID (COPACKAGED)
Indications Treated
HIV InfectionHIV-1 InfectionHuman Immunodeficiency VirusCoronavirus Disease 2019
All Drugs Targeting CYP3A
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| LOPINAVIR AND RITONAVIR | MACLEODS PHARMS LTD | 2016 | 1 | |
| KALETRA | AbbVie | 2000 | 1 | |
| PREZCOBIX | Johnson & Johnson | 2015 | 1 | Infectious Disease |
| GENVOYA | Gilead Sciences | 2015 | 1 | |
| SYMTUZA | Johnson & Johnson | 2018 | 1 | Infectious Disease |
| TYBOST | Gilead Sciences | 2014 | 1 | |
| EVOTAZ | Bristol-Myers Squibb | 2015 | 1 | |
| PAXLOVID (COPACKAGED) | Pfizer | 2023 | 1 | Infectious Disease |